NEW YORK, NY / ACCESSWIRE / January 25, 2018 / U.S. markets were mixed Wednesday as technology stocks pressured the S&P 500 and the Nasdaq lower, while the Dow rose on strength from the financial sector. The S&P 500 Index declined 0.06 percent to close at 2,837.54, while the Nasdaq Composite Index fell 0.61 percent to close at 7,415.06. The Dow Jones Industrial Average fell by as much as 104 points before settling to close at 26,252.12, an increase of 0.16 percent. All three major indexes are up between 6 percent and 7.5 percent year-to-date.
RDI Initiates Coverage on:
Anthera Pharmaceuticals, Inc.
Cara Therapeutics, Inc.
Anthera Pharmaceuticals stock jumped 21.43% Wednesday, to close the day at $1.87. The stock recorded a trading volume of 3,966,537 shares, which was above its three months average volume of 506,016 shares. In the last year, Anthera Pharmaceuticals shares have traded in a range of 1.20 - 6.24. The share price has gained 55.83% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.52 is below its 200-day moving average of $1.56. Shares of Anthera Pharmaceuticals have gained roughly 24.67 percent in the past month and are up 13.33 percent year-to-date.
Access RDI's Anthera Pharmaceuticals, Inc. Research Report at:
On Wednesday, shares of Cara Therapeutics recorded a trading volume of 7,372,760 shares, which was above the three months average volume of 890,419 shares. The stock ended the day 17.20% higher at 16.08. The share price has gained 44.73% from its 52 week low with a 52 week trading range of 11.11 - 28.50. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $12.74 is below its 200-day moving average of $13.18. Shares of Cara Therapeutics have gained roughly 31.37 percent in the past month and are up 31.37 percent year-to-date.
Access RDI's Cara Therapeutics, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute